Europe Drug Forecasts to 2026: Real-world, country level historic product sales and consensus based forecasts.

Conduct European market sizing, R&D horizon scanning and price comparison utilising real world government and company reported sales data with country level, consensus based product forecasts to 2026.

- **European Market Sizing**: Forecasts for key branded products
- **Model Future Pipeline Impact**: Forecasts for full R&D pipeline
- **Government and Company Reported Drug Sales**: Compare with audit based systems
- **Pricing**: Perform comparative pricing analysis
- **Generic Market Analysis**: Generic sales, volume & pricing
- **European Launch Dates**: Launch dates for products in European countries
European Market Sizing
Forecasts for key branded drugs at a European country level – market value of over €100bn in 2026
• Conduct future market assessment
• Map future trends of key marketed drugs
• Profile in line products

Model Future Pipeline Impact
Full forecast pipeline for R&D products launching in Europe – market value €30bn
• Map key pipeline assets that are likely to launch by 2026 and measure impact
• Identify new medicines and how they impact therapy areas

Competitive Landscaping
Historical government and company reported sales data (EU 5 and other key markets)
• Compare product performance across key European markets
• Map uptake trends and drivers across European countries
• Understand drug launch timelines across 20 countries

Pricing Comparison Analysis Across Countries
Ex-factory pricing data for Germany, France, Italy, England, Poland, Spain and other key markets
• Perform comparative analysis across EU 6 countries for key products
• Use price/DDD benchmark to inform quick assessment of new assets

A pioneering methodology for European country level drug forecasts

Powered by Evaluate’s industry standard consensus forecasts and broken out on a European country level using:
• European historical data – government and company reported
• Coupled with Evaluate’s proprietary methodology inputs:
  – Estimated European launch timelines of R&D products
  – Analogue methodology to model forecast for R&D products
  – European uptake patterns and country launch timings
  – Expected European generic entry

Copyright © 2021 Evaluate Ltd. All rights reserved.
Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalized, expert support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

**Evaluate Omnium** provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential.

**Evaluate Pharma** offers a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2026, company financials, pipelines and deals.

**Evaluate Medtech** tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2026, company financials and more.

**Evaluate Custom Solutions** improves your strategic decision-making with customized solutions and deep insights that draw on our industry expertise and trusted commercial intelligence.

**Evaluate Vantage** provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate’s commercial intelligence.